Tag: tavi
ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse...
Edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation (TAVI), new...
NOAC therapy leads to increased risk of ischaemic events following TAVI...
The one-year bleeding risk for patients with atrial fibrillation (AF) who undergo transcatheter aortic valve implantation (TAVI) is the same whether they are receiving...
First-in-human data demonstrate safety and efficacy of new lead for temporary...
A first-in-human study has shown that a new temporary lead for cardiac pacing (Tempo Lead, BioTrace Medical) is safe and effective for use in...
FDA clears temporary pacing lead for use during TAVI and other...
BioTrace Medical has received FDA 510(k) clearance for its Tempo Lead, which a press release describes as an innovative temporary pacing lead that has...